Daniel Long
Patrimonio netto: 3 M $ in data 31/05/2026
Patrimonio netto: 3 M $ in data 31/05/2026
Daniel Long currently works at Septerna, Inc., as Senior Vice President-Drug Discovery from 2021.
Dr. Long also formerly worked at Theravance Biopharma, Inc., as Vice President & Head-Medical Chemistry & Biology from 2001 to 2021.
Dr. Long received his undergraduate degree, graduate degree, and doctorate degree from the University of Oxford.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
SEPTERNA, INC. 0,21% | 22/06/2026 | 96.412 ( 0,21% ) | 3 M $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| SEPTERNA, INC. | Corporate Officer/Principal | 01/12/2021 |
| Società | Posizione | Fine |
|---|---|---|
| THERAVANCE BIOPHARMA, INC. | Corporate Officer/Principal | 01/12/2021 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 3 |
|---|---|
University of Oxford
University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Theravance Biopharma, Inc.
Theravance Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of human therapeutics products for respiratory diseases | Health Technology |
Septerna, Inc.
Septerna, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that discovers and develops G protein-coupled receptor oral small molecule products for the treatment of hypoparathyroidism | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale